Received this email from a friend? Sign up now |
---|
March 14, 2024 This message includes updates on respiratory viruses from CDC. |
---|
Older Adults Now Able to Receive Additional Dose of Updated COVID-19 VaccineCDC recommends that adults ages 65 years and older receive an additional updated 2023-2024 COVID-19 vaccine dose. Adults 65 years and older are disproportionately impacted by COVID-19, with more than half of COVID-19 hospitalizations during October 2023 to December 2023 occurring in this age group. The recommendation acknowledges the increased risk of severe disease from COVID-19 in older adults, along with the currently available data on vaccine effectiveness. Data continues to show the importance of vaccination to protect those most at risk for severe outcomes of COVID-19. An additional dose of the updated COVID-19 vaccine may restore protection that has waned since a fall vaccine dose, providing increased protection to adults ages 65 years and older. |
---|
International Long COVID Awareness DayMarch 15 is International Long COVID Awareness Day. This year's theme is "Confront Long COVID." It is important to recognize and raise awareness of Long COVID as a real and serious infection-associated chronic condition that has affected millions of people across the United States. CDC and other federal partners and stakeholders are actively working to address gaps in the understanding of Long COVID and the needs of people with Long COVID. Please join us in supporting people with this condition. Together, we can confront Long COVID.
|
---|
CDC study shows effectiveness of RSV immunization for infantsEarly CDC surveillance data show that nirsevimab is 90% effective at preventing hospitalizations associated with respiratory syncytial virus (RSV) in babies. These findings support CDC’s current recommendations for administration of nirsevimab for babies younger than 8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8–19 months at increased risk for severe RSV disease. To reduce the risk of RSV-associated hospitalization, all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab. New or expecting parents should talk to their providers about RSV and make a plan for the 2024-2025 season.
|
---|
2023–2024 Seasonal Flu Vaccine EffectivenessA new CDC report provides interim vaccine effectiveness (VE) estimates for 2023-2024 flu vaccines in the United States. One VE Network showed:
CDC recommends that everyone 6 months and older who has not yet received a flu vaccine this season get vaccinated now.
|
---|
|
---|